Danish Heart Foundation, Copenhagen, Denmark.
Department of Cardiology, Herlev and Gentofte University Hospital, Copenhagen, Denmark; Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
J Am Coll Cardiol. 2023 Sep 5;82(10):971-981. doi: 10.1016/j.jacc.2023.06.024.
Due to improved management, diagnosis, and care of myocardial infarction (MI), patients may now survive long enough to increasingly develop serious noncardiovascular conditions.
This study aimed to test this hypothesis by investigating the temporal trends in noncardiovascular morbidity and mortality following MI.
We conducted a registry-based nationwide cohort study of all Danish patients with MI during 2000 to 2017. Outcomes were cardiovascular and noncardiovascular mortality, incident cancer, incident renal disease, and severe infectious disease.
From 2000 to 2017, 136,293 consecutive patients were identified (63.2% men, median age 69 years). The 1-year risk of cardiovascular mortality between 2000 to 2002 and 2015 to 2017 decreased from 18.4% to 7.6%, whereas noncardiovascular mortality decreased from 5.8% to 5.0%. This corresponded to an increase in the proportion of total 1-year mortality attributed to noncardiovascular causes from 24.1% to 39.5%. Furthermore, increases in 1-year risk of incident cancer (1.9%-2.4%), incident renal disease (1.0%-1.6%), and infectious disease (5.5%-9.1%) were observed (all P trend <0.01). In analyses standardized for changes in patient characteristics, the increased risk of cancer in 2015 to 2017 compared with 2000 to 2002 was no longer significant (standardized risk ratios for cancer: 0.99 [95% CI: 0.91-1.07]; renal disease: 1.28 [95% CI: 1.15-1.41]; infectious disease: 1.28 [95% CI: 1.23-1.34]).
Although cardiovascular mortality following MI improved substantially during 2000 to 2017, the risk of noncardiovascular morbidity increased. Moreover, noncardiovascular causes constitute an increasing proportion of post-MI mortality. These findings suggest that further attention on noncardiovascular outcomes is warranted in guidelines and clinical practice and should be considered in the design of future clinical trials.
由于心肌梗死(MI)的管理、诊断和治疗得到改善,患者现在可能能够存活足够长的时间,从而逐渐出现严重的非心血管疾病。
本研究旨在通过调查 MI 后非心血管发病率和死亡率的时间趋势来检验这一假设。
我们进行了一项基于登记的全国性队列研究,纳入了 2000 年至 2017 年期间丹麦所有 MI 患者。结局为心血管和非心血管死亡率、新发癌症、新发肾脏疾病和严重感染性疾病。
2000 年至 2017 年期间,共确定了 136293 例连续患者(63.2%为男性,中位年龄 69 岁)。2000 年至 2002 年和 2015 年至 2017 年 1 年的心血管死亡率风险从 18.4%降至 7.6%,而非心血管死亡率从 5.8%降至 5.0%。这对应于归因于非心血管原因的 1 年总死亡率比例从 24.1%增加到 39.5%。此外,观察到 1 年新发癌症(1.9%-2.4%)、新发肾脏疾病(1.0%-1.6%)和传染病(5.5%-9.1%)风险增加(均 P 趋势<0.01)。在按患者特征变化标准化的分析中,与 2000 年至 2002 年相比,2015 年至 2017 年癌症风险的增加不再显著(癌症的标准化风险比:0.99[95%CI:0.91-1.07];肾脏疾病:1.28[95%CI:1.15-1.41];传染病:1.28[95%CI:1.23-1.34])。
尽管 2000 年至 2017 年期间 MI 后心血管死亡率显著改善,但非心血管发病率的风险增加。此外,非心血管原因构成 MI 后死亡率的比例不断增加。这些发现表明,在指南和临床实践中需要进一步关注非心血管结局,并应在未来临床试验的设计中考虑到这一点。